{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:13:57Z","timestamp":1792815237449,"version":"4.5.0"},"reference-count":98,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Seville","award":["202200000421"],"award-info":[{"award-number":["202200000421"]}]},{"name":"University of Seville","award":["2023\/00000482"],"award-info":[{"award-number":["2023\/00000482"]}]},{"name":"University of Seville","award":["RYC2021-031256-I"],"award-info":[{"award-number":["RYC2021-031256-I"]}]},{"DOI":"10.13039\/501100004837","name":"Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["202200000421"],"award-info":[{"award-number":["202200000421"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["2023\/00000482"],"award-info":[{"award-number":["2023\/00000482"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["RYC2021-031256-I"],"award-info":[{"award-number":["RYC2021-031256-I"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Dendritic cells (DCs) serve as professional antigen-presenting cells (APC) bridging innate and adaptive immunity, playing an essential role in triggering specific cellular and humoral responses against tumor and infectious antigens. Consequently, various DC-based antitumor therapeutic strategies have been developed, particularly vaccines, and have been intensively investigated specifically in the context of acute myeloid leukemia (AML). This hematological malignancy mainly affects the elderly population (those aged over 65), which usually presents a high rate of therapeutic failure and an unfavorable prognosis. In this review, we examine the current state of development and progress of vaccines in AML. The findings evidence the possible administration of DC-based vaccines as an adjuvant treatment in AML following initial therapy. Furthermore, the therapy demonstrates promising outcomes in preventing or delaying tumor relapse and exhibits synergistic effects when combined with other treatments during relapses or disease progression. On the other hand, the remarkable success observed with RNA vaccines for COVID-19, delivered in lipid nanoparticles, has revealed the efficacy and effectiveness of these types of vectors, prompting further exploration and their potential application in AML, as well as other neoplasms, loading them with tumor RNA.<\/jats:p>","DOI":"10.3390\/vaccines12020165","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T03:22:31Z","timestamp":1707189751000},"page":"165","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Dendritic Cells as a Therapeutic Strategy in Acute Myeloid Leukemia: Vaccines"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5591-7877","authenticated-orcid":false,"given":"Francisca","family":"Palomares","sequence":"first","affiliation":[{"name":"Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, Av. Sanchez Pizjuan s\/n, 41009 Seville, Spain"},{"name":"Institute of Biomedicine of Seville (IBiS) HUVR\/CSIC\/University of Seville, Avda. Manuel Siurot s\/n, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Pina","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, Av. Sanchez Pizjuan s\/n, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8716-1437","authenticated-orcid":false,"given":"Hala","family":"Dakhaoui","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, Av. Sanchez Pizjuan s\/n, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Leiva-Castro","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, Av. Sanchez Pizjuan s\/n, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Munera-Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, Av. Sanchez Pizjuan s\/n, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cejudo-Guillen","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine of Seville (IBiS) HUVR\/CSIC\/University of Seville, Avda. Manuel Siurot s\/n, 41013 Seville, Spain"},{"name":"Department of Pharmacology, Pediatry, and Radiology, School of Medicine, University of Seville, Av. Sanchez Pizjuan s\/n, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Granados","sequence":"additional","affiliation":[{"name":"Distrito Sanitario de Atenci\u00f3n Primaria M\u00e1laga, Sistema Sanitario P\u00fablico de Andaluc\u00eda, 29004 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6598-2039","authenticated-orcid":false,"given":"Gonzalo","family":"Alba","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, Av. Sanchez Pizjuan s\/n, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-2792","authenticated-orcid":false,"given":"Consuelo","family":"Santa-Maria","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Pharmacy, University of Seville, 41012 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Sobrino","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, Av. Sanchez Pizjuan s\/n, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3727-1843","authenticated-orcid":false,"given":"Soledad","family":"Lopez-Enriquez","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, University of Seville, Av. Sanchez Pizjuan s\/n, 41009 Seville, Spain"},{"name":"Institute of Biomedicine of Seville (IBiS) HUVR\/CSIC\/University of Seville, Avda. Manuel Siurot s\/n, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-16-2821","article-title":"Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8(+) T-cell Infiltration","volume":"23","author":"Lee","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-immunol-061020-053707","article-title":"Dendritic Cells Revisited","volume":"39","author":"Cardoso","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1182553","DOI":"10.3389\/fimmu.2023.1182553","article-title":"Transcriptional regulation of dendritic cell development and function","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Van Acker, H.H., Versteven, M., Lichtenegger, F.S., Roex, G., Campillo-Davo, D., Lion, E., Subklewe, M., Van Tendeloo, V.F., Berneman, Z.N., and Anguille, S. (2019). Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia. J. Clin. Med., 8.","DOI":"10.3390\/jcm8050579"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/cdd.2014.89","article-title":"Regulation of hematopoietic and leukemic stem cells by the immune system","volume":"22","author":"Riether","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)61727-9","article-title":"Acute myeloid leukaemia in adults","volume":"381","author":"Ferrara","year":"2013","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fimmu.2020.00924","article-title":"Dendritic Cells and Their Role in Immunotherapy","volume":"11","author":"Gardner","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"923647","DOI":"10.3389\/fimmu.2022.923647","article-title":"Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: Mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"704776","DOI":"10.3389\/fimmu.2021.704776","article-title":"Recent Advances and Future Perspective of DC-Based Therapy in NSCLC","volume":"12","author":"Piet","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A natural killer\u2013dendritic cell axis defines checkpoint therapy\u2013responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e001963","DOI":"10.1136\/jitc-2020-001963","article-title":"Human CD141(+) dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model","volume":"9","author":"Lee","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Barbullushi, K., Rampi, N., Serpenti, F., Sciume, M., Fabris, S., De Roberto, P., and Fracchiolla, N.S. (2022). Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?. Cancers, 14.","DOI":"10.3390\/cancers14122994"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Najafi, S., and Mortezaee, K. (2023). Advances in dendritic cell vaccination therapy of cancer. Biomed. Pharmacother., 164.","DOI":"10.1016\/j.biopha.2023.114954"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103607","DOI":"10.1016\/j.critrevonc.2022.103607","article-title":"Diagnosis and treatment of therapy-related acute myeloid leukemia","volume":"171","author":"Strickland","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: A unified nomenclature based on ontogeny","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic Cells and Cancer Immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.cell.2019.09.035","article-title":"Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity","volume":"179","author":"Brown","year":"2019","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"eaah4573","DOI":"10.1126\/science.aah4573","article-title":"Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors","volume":"356","author":"Villani","year":"2017","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"eabm9409","DOI":"10.1126\/sciimmunol.abm9409","article-title":"Human dendritic cells in cancer","volume":"7","author":"Kvedaraite","year":"2022","journal-title":"Sci. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41590-018-0136-9","article-title":"Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells","volume":"19","author":"Rodrigues","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41590-019-0420-3","article-title":"Plasmacytoid dendritic cells develop from Ly6D(+) lymphoid progenitors distinct from the myeloid lineage","volume":"20","author":"Dress","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Solano-Galvez, S.G., Tovar-Torres, S.M., Tron-Gomez, M.S., Weiser-Smeke, A.E., Alvarez-Hernandez, D.A., Franyuti-Kelly, G.A., Tapia-Moreno, M., Ibarra, A., Gutierrez-Kobeh, L., and Vazquez-Lopez, R. (2018). Human Dendritic Cells: Ontogeny and Their Subsets in Health and Disease. Med. Sci., 6.","DOI":"10.3390\/medsci6040088"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.molimm.2020.07.006","article-title":"Novel concepts in plasmacytoid dendritic cell (pDC) development and differentiation","volume":"126","author":"Rodrigues","year":"2020","journal-title":"Mol. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1471-4906(02)02281-0","article-title":"Immature, semi-mature and fully mature dendritic cells: Which signals induce tolerance or immunity?","volume":"23","author":"Lutz","year":"2002","journal-title":"Trends Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nature06175","article-title":"Taking dendritic cells into medicine","volume":"449","author":"Steinman","year":"2007","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fimmu.2012.00123","article-title":"Therapeutic potential of semi-mature dendritic cells for tolerance induction","volume":"3","author":"Lutz","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fimmu.2013.00438","article-title":"Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity","volume":"4","author":"Dudek","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Khan, F.U., Khongorzul, P., Raki, A.A., Rajasekaran, A., Gris, D., and Amrani, A. (2022). Dendritic Cells and Their Immunotherapeutic Potential for Treating Type 1 Diabetes. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094885"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1126\/science.1137971","article-title":"Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation","volume":"316","author":"Burgdorf","year":"2007","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1084\/jem.20092720","article-title":"Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC","volume":"207","author":"Lauterbach","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"eaav3942","DOI":"10.1126\/sciimmunol.aav3942","article-title":"IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer","volume":"5","author":"Hubert","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/1078-0432.CCR-04-0684","article-title":"Dendritic cell infiltration and prognosis of early stage breast cancer","volume":"10","author":"Treilleux","year":"2004","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1158\/0008-5472.CAN-12-2271","article-title":"Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells","volume":"72","author":"Conrad","year":"2012","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Oshi, M., Newman, S., Tokumaru, Y., Yan, L., Matsuyama, R., Kalinski, P., Endo, I., and Takabe, K. (2020). Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC). Cancers, 12.","DOI":"10.3390\/cancers12113342"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1074-7613(00)80149-1","article-title":"Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo","volume":"11","author":"Randolph","year":"1999","journal-title":"Immunity"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/imm.12888","article-title":"Human dendritic cell subsets: An update","volume":"154","author":"Collin","year":"2018","journal-title":"Immunology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3389\/fimmu.2020.01406","article-title":"Monocyte-Derived Dendritic Cell Differentiation in Inflammatory Arthritis Is Regulated by the JAK\/STAT Axis via NADPH Oxidase Regulation","volume":"11","author":"Marzaioli","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"624","DOI":"10.4049\/jimmunol.1501202","article-title":"Monocyte-Derived Dendritic Cells Promote Th Polarization, whereas Conventional Dendritic Cells Promote Th Proliferation","volume":"196","author":"Chow","year":"2016","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"13720","DOI":"10.1038\/ncomms13720","article-title":"The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity","volume":"7","author":"Laoui","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fimmu.2014.00165","article-title":"Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets","volume":"5","author":"Wimmers","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3389\/fimmu.2015.00584","article-title":"Monocyte-Derived Dendritic Cells Are Essential for CD8(+) T Cell Activation and Antitumor Responses After Local Immunotherapy","volume":"6","author":"Kuhn","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0092-8674(01)00449-4","article-title":"Dendritic cells: Specialized and regulated antigen processing machines","volume":"106","author":"Mellman","year":"2001","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41401-020-0415-5","article-title":"Ex vivo pulsed dendritic cell vaccination against cancer","volume":"41","author":"Gu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e1190","DOI":"10.1002\/cti2.1190","article-title":"BDCA1(+) cDC2s, BDCA2(+) pDCs and BDCA3(+) cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients","volume":"9","author":"Ouaguia","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1172\/JCI93303","article-title":"Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy","volume":"128","author":"Hailemichael","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Schwepcke, C., Klauer, L.K., Deen, D., Amberger, D.C., Fischer, Z., Doraneh-Gard, F., Gunsilius, C., Hirn-Lopez, A., Kroell, T., and Tischer, J. (2022). Generation of Leukaemia-Derived Dendritic Cells (DC(leu)) to Improve Anti-Leukaemic Activity in AML: Selection of the Most Efficient Response Modifier Combinations. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158333"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1182\/blood.V93.3.780","article-title":"Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses","volume":"93","author":"Choudhury","year":"1999","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Dorrie, J., Schaft, N., Schuler, G., and Schuler-Thurner, B. (2020). Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12020092"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e000329","DOI":"10.1136\/jitc-2019-000329","article-title":"TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: Link between T-cell activation and clinical responses in advanced melanoma","volume":"8","author":"Claerhout","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1111523","DOI":"10.3389\/fimmu.2023.1111523","article-title":"An mRNA mix redirects dendritic cells towards an antiviral program, inducing anticancer cytotoxic stem cell and central memory CD8(+) T cells","volume":"14","author":"Locy","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/79519","article-title":"Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells","volume":"6","author":"Nair","year":"2000","journal-title":"Nat. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/cncr.30696","article-title":"Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia","volume":"123","author":"Khoury","year":"2017","journal-title":"Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4049\/jimmunol.1701024","article-title":"Dendritic Cell-Based Cancer Vaccines","volume":"200","author":"Santos","year":"2018","journal-title":"J. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc11-0472","article-title":"Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"734256","DOI":"10.3389\/fimmu.2022.734256","article-title":"Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands","volume":"13","author":"Versteven","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1084\/jem.20021598","article-title":"Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance","volume":"196","author":"Bonifaz","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2217\/imt.15.35","article-title":"Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma","volume":"7","author":"Johnson","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1038\/s41467-019-13368-y","article-title":"Engineering dendritic cell vaccines to improve cancer immunotherapy","volume":"10","author":"Perez","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jconrel.2022.03.033","article-title":"Delivery of mRNA for regulating functions of immune cells","volume":"345","author":"Shi","year":"2022","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"ref_69","first-page":"38","article-title":"Acute Myeloid Leukemia: A Review","volume":"103","author":"Pelcovits","year":"2020","journal-title":"Rhode Isl. Med. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","article-title":"Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia","volume":"130","author":"Anguille","year":"2017","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00262-022-03268-4","article-title":"Invariant NKT cells metabolically adapt to the acute myeloid leukaemia environment","volume":"72","author":"Stavrou","year":"2023","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/s41375-023-01980-3","article-title":"WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy","volume":"37","author":"Floisand","year":"2023","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, L.J., Guillerey, C., and Radford, K.J. (2019). Can Dendritic Cell Vaccination Prevent Leukemia Relapse?. Cancers, 11.","DOI":"10.3390\/cancers11060875"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Abadir, E., Gasiorowski, R.E., Silveira, P.A., Larsen, S., and Clark, G.J. (2020). Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia?. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020554"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"624742","DOI":"10.3389\/fonc.2021.624742","article-title":"Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"11","author":"Wong","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e1141","DOI":"10.1002\/cti2.1141","article-title":"Human CLEC9A antibodies deliver Wilms\u2019 tumor 1 (WT1) antigen to CD141(+) dendritic cells to activate naive and memory WT1-specific CD8(+) T cells","volume":"9","author":"Pearson","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00262-017-2040-9","article-title":"Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy","volume":"66","author":"Sander","year":"2017","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","article-title":"Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed\/Refractory Acute Myeloid Leukemia","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/cncr.33690","article-title":"A phase 1b\/2 study of azacitidine with PD-L1 antibody avelumab in relapsed\/refractory acute myeloid leukemia","volume":"127","author":"Saxena","year":"2021","journal-title":"Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/bloodadvances.2021006909","article-title":"Using stroma-anchoring cytokines to augment ADCC: A phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse","volume":"6","author":"Berdel","year":"2022","journal-title":"Blood Adv."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1080\/10428194.2022.2062345","article-title":"A multi-arm phase Ib\/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed\/refractory acute myeloid leukemia","volume":"63","author":"Short","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1007\/s00262-022-03202-8","article-title":"First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: A single-center experience","volume":"71","author":"Kreutmair","year":"2022","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/bloodadvances.2021006255","article-title":"GM-CSF secreting leukemia cell vaccination for MDS\/AML after allogeneic HSCT: A randomized, double-blinded, phase 2 trial","volume":"6","author":"Ho","year":"2022","journal-title":"Blood Adv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ajh.24014","article-title":"WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides","volume":"90","author":"Brayer","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1080\/21645515.2021.1943991","article-title":"A phase I\/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients","volume":"17","author":"Chevallier","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e98368","DOI":"10.1172\/jci.insight.98368","article-title":"Efficacy of intracellular immune checkpoint-silenced DC vaccine","volume":"3","author":"Wang","year":"2018","journal-title":"JCI Insight"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14653240902960411","article-title":"Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial","volume":"11","author":"Nijs","year":"2009","journal-title":"Cytotherapy"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e1117","DOI":"10.1002\/cti2.1117","article-title":"Toll-like receptor 7\/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: Results of a phase I trial","volume":"9","author":"Lichtenegger","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-17-1792","article-title":"NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome","volume":"24","author":"Griffiths","year":"2018","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1159\/000512452","article-title":"Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia","volume":"47","author":"Amberger","year":"2020","journal-title":"Transfus. Med. Hemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"368ra171","DOI":"10.1126\/scitranslmed.aag1298","article-title":"Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions","volume":"8","author":"Rosenblatt","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Hernandez, S.S., Jakobsen, M.R., and Bak, R.O. (2022). Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911397"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-018-2198-9","article-title":"A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia","volume":"67","author":"Santegoets","year":"2018","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"232ra251","DOI":"10.1126\/scitranslmed.3008068","article-title":"Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205","volume":"6","author":"Dhodapkar","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3389\/fphar.2018.00980","article-title":"Optimization of the Linker Length of Mannose-Cholesterol Conjugates for Enhanced mRNA Delivery to Dendritic Cells by Liposomes","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s13238-013-3916-x","article-title":"Enhancement of DC-mediated anti-leukemic immunity in vitro by WT1 antigen and CpG co-encapsulated in PLGA microparticles","volume":"4","author":"Zhang","year":"2013","journal-title":"Protein Cell"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/2\/165\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:55:34Z","timestamp":1760104534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/2\/165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":98,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["vaccines12020165"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12020165","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]}}}